Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CLL Pharma and Leurquin-Mediolanum announced today that enrollment has begun in a Phase 1b clinical trial of Syn1002 to demonstrate its proof of concept in validated human pain models.
This study follows the completion of the Phase 1 single dose-escalation study of Syn1002 which showed that the compound is very well tolerated in healthy volunteers. Syn1002 is a lead drug candidate, which has shown efficacy in various animal models of inflammatory and neuropathic pain and also in preclinical models of arthritis and Crohn’s disease.
Help employers find you! Check out all the jobs and post your resume.
